$45.3
0.13%
Downside
Day's Volatility :6.91%
Upside
6.79%
10.33%
Downside
52 Weeks Volatility :59.2%
Upside
54.5%
Period | Exact Sciences Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.82% | 6.5% | 0.0% |
6 Months | -24.77% | 7.1% | 0.0% |
1 Year | -49.6% | 9.8% | 0.0% |
3 Years | -57.36% | 14.2% | -20.2% |
Market Capitalization | 8.9B |
Book Value | $17.04 |
Earnings Per Share (EPS) | -1.31 |
PEG Ratio | -1.07 |
Wall Street Target Price | 80.39 |
Profit Margin | -9.48% |
Operating Margin TTM | -15.12% |
Return On Assets TTM | -3.15% |
Return On Equity TTM | -7.76% |
Revenue TTM | 2.5B |
Revenue Per Share TTM | 14.0 |
Quarterly Revenue Growth YOY | 5.800000000000001% |
Gross Profit TTM | 1.5B |
EBITDA | -108.4M |
Diluted Eps TTM | -1.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.15 |
EPS Estimate Next Year | -0.2 |
EPS Estimate Current Quarter | -0.47 |
EPS Estimate Next Quarter | -0.23 |
What analysts predicted
Upside of 77.46%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 454.5M | ↑ 70.86% |
Net Income | -175.1M | ↑ 53.11% |
Net Profit Margin | -38.54% | ↑ 4.47% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 876.3M | ↑ 92.82% |
Net Income | -84.0M | ↓ 52.04% |
Net Profit Margin | -9.59% | ↑ 28.95% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 70.19% |
Net Income | -848.5M | ↑ 910.24% |
Net Profit Margin | -56.9% | ↓ 47.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 18.49% |
Net Income | -595.6M | ↓ 29.81% |
Net Profit Margin | -33.71% | ↑ 23.19% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 17.95% |
Net Income | -623.5M | ↑ 4.68% |
Net Profit Margin | -29.91% | ↑ 3.8% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.5B | ↑ 19.93% |
Net Income | -204.1M | ↓ 67.26% |
Net Profit Margin | -8.17% | ↑ 21.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 553.0M | ↑ 5.72% |
Net Income | -127.7M | ↓ 14.13% |
Net Profit Margin | -23.1% | ↑ 5.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 602.5M | ↑ 8.94% |
Net Income | -74.2M | ↓ 41.95% |
Net Profit Margin | -12.31% | ↑ 10.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 622.1M | ↑ 3.26% |
Net Income | -81.0M | ↑ 9.27% |
Net Profit Margin | -13.02% | ↓ 0.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 628.3M | ↑ 1.0% |
Net Income | 794.0K | ↓ 100.98% |
Net Profit Margin | 0.13% | ↑ 13.15% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 646.9M | ↑ 2.95% |
Net Income | -49.8M | ↓ 6367.76% |
Net Profit Margin | -7.69% | ↓ 7.82% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 637.5M | ↓ 1.45% |
Net Income | -110.2M | ↑ 121.49% |
Net Profit Margin | -17.29% | ↓ 9.6% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 154.61% |
Total Liabilities | 843.1M | ↑ 978.91% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↑ 130.03% |
Total Liabilities | 1.2B | ↑ 44.44% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 40.49% |
Total Liabilities | 2.1B | ↑ 72.59% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 6.7B | ↑ 35.73% |
Total Liabilities | 3.3B | ↑ 56.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.2B | ↓ 6.85% |
Total Liabilities | 3.2B | ↓ 3.44% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↑ 3.93% |
Total Liabilities | 3.3B | ↑ 4.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.2B | ↓ 1.26% |
Total Liabilities | 3.2B | ↓ 0.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↑ 1.24% |
Total Liabilities | 3.2B | ↑ 1.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↑ 0.81% |
Total Liabilities | 3.3B | ↑ 1.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↑ 1.03% |
Total Liabilities | 3.3B | ↑ 0.02% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↑ 0.79% |
Total Liabilities | 3.3B | ↑ 0.8% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↓ 1.47% |
Total Liabilities | 3.2B | ↓ 2.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -69.3M | ↓ 3.34% |
Investing Cash Flow | -781.9M | ↑ 386.25% |
Financing Cash Flow | 934.1M | ↑ 257.97% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -115.0M | ↑ 65.9% |
Investing Cash Flow | -121.1M | ↓ 84.52% |
Financing Cash Flow | 253.2M | ↓ 72.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 136.5M | ↓ 218.67% |
Investing Cash Flow | -702.0M | ↑ 479.85% |
Financing Cash Flow | 1.9B | ↑ 642.4% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -102.2M | ↓ 174.91% |
Investing Cash Flow | -1.1B | ↑ 54.14% |
Financing Cash Flow | 8.5M | ↓ 99.55% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -223.6M | ↑ 118.67% |
Investing Cash Flow | 74.1M | ↓ 106.84% |
Financing Cash Flow | 76.5M | ↑ 802.8% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 52.0M | ↓ 227.15% |
Investing Cash Flow | -58.2M | ↓ 189.47% |
Financing Cash Flow | 10.1M | ↑ 4199.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.2M | ↓ 173.44% |
Investing Cash Flow | 82.9M | ↓ 242.61% |
Financing Cash Flow | 133.6M | ↑ 1222.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 100.4M | ↓ 362.79% |
Investing Cash Flow | 66.5M | ↓ 19.85% |
Financing Cash Flow | 16.0M | ↓ 87.99% |
Sell
Neutral
Buy
Exact Sciences Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Exact Sciences Corporation | 9.51% | -24.77% | -49.6% | -57.36% | -58.99% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Exact Sciences Corporation | NA | NA | -1.07 | -1.15 | -0.08 | -0.03 | NA | 17.04 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Exact Sciences Corporation | Buy | $8.9B | -58.99% | NA | -9.48% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Exact Sciences Corporation
Revenue is down for the last 2 quarters, 646.88M → 637.52M (in $), with an average decrease of 1.5% per quarter
Netprofit is down for the last 3 quarters, 794.0K → -110.22M (in $), with an average decrease of 3244.6% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 54.7%
In the last 3 years, Exact Sciences Corporation has experienced a drawdown of -57.4%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 47.2%
Vanguard Group Inc
Capital World Investors
JPMorgan Chase & Co
BlackRock Inc
Wellington Management Company LLP
State Street Corporation
Exact Sciences Corporation’s price-to-earnings ratio stands at None
Read Moreexact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Organization | Exact Sciences Corporation |
Employees | 6500 |
CEO | Mr. Kevin T. Conroy |
Industry | Health Technology |